Literature DB >> 6454381

Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

K Hirai, A Ito, Y Abe, S Suzue, T Irikura, M Inoue, S Mitsuhashi.   

Abstract

Dose for dose, AM-715 was at least five times as active as pipemidic acid and nalidixic acid against systemic and urinary bladder-kidney infections in mice.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6454381      PMCID： PMC181380          DOI： 10.1128/AAC.19.1.188

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  Pipemidic acid: its activities against various experimental infections.

Authors:  M Shimizu; Y Takdase; S Nakamura; H Katae; A Minami
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

2.  Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties.

Authors:  M Shimizu; Y Takase; S Nakamura; H Katae; A Minami
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

3.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191
  3 in total
  23 in total

1.  Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria.

Authors:  S J Wood; S Shadomy
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

2.  Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.

Authors:  D L Shungu; V Tutlane; H H Gadebusch
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

3.  Potential usefulness of norfloxacin in the treatment of urinary tract infections.

Authors:  S R Norrby
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

4.  Bioassay procedures for norfloxacin.

Authors:  J Bland; A Edison; J Huber
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

5.  Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.

Authors:  J Shimada; T Yamaji; Y Ueda; H Uchida; H Kusajima; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors:  M Y Khan; Y Siddiqui; R P Gruninger
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

7.  Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa.

Authors:  K Hirai; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

8.  Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit.

Authors:  R W Darrell; S M Modak; C L Fox
Journal:  Trans Am Ophthalmol Soc       Date:  1984

9.  In vitro and in vivo antibacterial activity of AT-2266.

Authors:  K Kouno; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

10.  Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.

Authors:  M Eandi; I Viano; F Di Nola; L Leone; E Genazzani
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.